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Background: During inflammation, 
myeloperoxidase (MPO) accumulates within the 
subendothelial matrix and produces the reactive 
oxidant hypochlorous acid (HOCl).  
Results: Subendothelial MPO catalyzes focal, 
HOCl-mediated matrix oxidation that disrupts 
cell-matrix adhesion and alters adhesion-
dependent cell signaling. 
Conclusion: MPO disrupts endothelial integrity 
and promotes cell signaling by targeted 
subendothelial matrix oxidation.  
Significance: MPO-mediated matrix oxidation has 
important implications for endothelial integrity 
and function during inflammation. 
 
SUMMARY  
During inflammation, myeloperoxidase (MPO) 
released by circulating leukocytes accumulates 
within the subendothelial matrix by binding to 
and transcytosing the endothelium. Oxidative 
reactions catalyzed by subendothelial-localized 
MPO are implicated as a key cause of 
endothelial dysfunction in inflammatory 
vascular diseases. Whilst the subendothelial 
matrix is a reactive target for MPO-derived 
oxidants in disease, the functional implications 
of oxidative matrix modification for the 
endothelium are largely unknown. Here we 
show that hypochlorous acid (HOCl) produced 
by endothelial-transcytosed MPO oxidizes the 
subendothelial matrix, involving covalent 
crosslinking of the adhesive matrix protein 
fibronectin. Real-time biosensor and live cell 
imaging studies showed that HOCl-mediated 
matrix oxidation triggers rapid membrane 
retraction from the substratum and adjacent 
cells (de-adhesion). This de-adhesion was linked 
with the alteration of Tyr-118 phosphorylation 
of paxillin, a key focal adhesion-dependent 
signaling process, as well as Rho kinase-
dependent myosin light chain-2 
phosphorylation. De-adhesion dynamics were 
dependent on the contractile state of cells, with 
myosin II inhibition with blebbistatin markedly 
attenuating the rate of membrane retraction. 
Rho kinase inhibition with Y-27632 also 
conferred protection, but not during the initial 
phase of membrane retraction, which was 
driven by pre-existing actomyosin tensile stress. 
Notably, diversion of MPO from HOCl 
production by thiocyanate and nitrite 
attenuated de-adhesion and associated signaling 
responses, despite the latter substrate 
supporting MPO-catalyzed fibronectin 
nitration. This study indicates that HOCl-
mediated matrix oxidation by subendothelial 
MPO deposits may play an important and 
previously unrecognized role in altering 
endothelial adhesion, signaling and integrity 
during inflammatory vascular disorders. 
 
The vascular endothelium performs vital functions 
in cardiovascular homeostasis by regulating the 
initiation and resolution of inflammatory 
responses and by controlling vascular tone. An 
important function of the endothelium in this 
regard is its production of nitric oxide (NO), 
which exerts anti-inflammatory actions by 
inhibiting leukocyte adhesion, inhibits platelet 
aggregation and regulates vascular tone by 
signaling for vasodilation in the adjacent vascular 
smooth muscle cells (1). The homeostatic 




properties of the endothelium are also dependent 
on its function as a continuous, semi-permeable 
barrier that tightly regulates the passage of 
nutrients, macromolecules, fluid and cells between 
the blood and the interstitial space (2,3). 
Inflammatory vascular diseases such as 
atherosclerosis are characterized by endothelial 
dysfunction manifested as a reduction in the 
bioactivity of endothelial-derived NO (1) and a 
loss of endothelial barrier integrity leading to 
endothelial hyper-permeability (4,5). Enhanced 
vascular oxidative stress during inflammation is 
implicated as a principal cause of compromised 
endothelial NO signaling (1) and barrier function 
(2,3) and accordingly there is significant interest in 
understanding the oxidative reactions involved. 
 Considerable clinical and experimental 
evidence supports that myeloperoxidase (MPO), 
an oxidant-generating heme enzyme released by 
activated leukocytes, plays a pathogenic role in 
impairing the signaling and vasodilatory function 
of endothelium-derived NO during inflammatory 
vascular disease. Thus, circulating MPO levels are 
elevated in coronary artery disease patients and the 
extent of this increase is an independent predictor 
of the incidence of endothelial dysfunction 
manifested as impaired endothelium-dependent 
vasorelaxation (6,7), as well as the prevalence and 
degree of coronary artery disease and clinical 
event risk in patients with acute coronary 
syndromes (8,9). Inflammatory stimuli that 
increase circulating MPO levels promote 
endothelial dysfunction in healthy animals and 
humans, with a deficiency in functional MPO 
conferring protection (10,11). Intravascular 
administration of MPO also impairs endothelial-
dependent vasorelaxation (11). Circulating MPO 
rapidly leaves the circulating compartment by 
binding to and transcytosing the endothelium, 
resulting in its accumulation within the 
subendothelial matrix, where it is anatomically 
positioned to impair the signaling and vasodilatory 
function of endothelium-derived NO by acting as a 
NO oxidase (10,12,13).  
 Subendothelial-localized MPO is not only 
positioned to interfere with NO signaling, but to 
generate reactive oxidants capable of altering the 
structure and function of extracellular matrix 
proteins (12,14-16). The potent chlorinating 
oxidant hypochlorous acid (HOCl) is the principal 
oxidant produced by MPO and is generated by 
oxidation of chloride ions (Cl-) in the presence of 
the co-substrate hydrogen peroxide (H2O2) 
(17,18). Thiocyanate (SCN−) and nitrite (NO2−) are 
also significant physiological substrates that divert 
the enzyme from HOCl production to the 
generation of the thiol-reactive oxidant 
hypothiocyanous acid (HOSCN) and the nitrating 
radical nitrogen dioxide (NO2), respectively (18). 
Various studies support that subendothelial matrix 
proteins are significant oxidative targets for MPO-
derived oxidants. Thus, MPO transcytosed by 
cultured endothelial cells binds to adhesive matrix 
substrate fibronectin, conferring specificity of 
MPO-catalyzed tyrosine nitration to this protein 
(12). In atherosclerotic coronary arteries and other 
inflamed vascular tissue from humans, MPO is 
characteristically found deposited within the 
subendothelium where it co-localizes with 
fibronectin-containing extracellular matrix and 
tyrosine-nitrated proteins (19). Extracellular 
deposits of MPO and HOCl-modified proteins are 
similarly detected within the vascular endothelium 
of human atherosclerotic arteries (20,21).  
 While oxidative modification of 
subendothelial matrix proteins by MPO-derived 
oxidants is a characteristic event during 
inflammatory vascular disease, the implications of 
this for endothelial cell morphology, signaling and 
phenotype are largely unknown. In the current 
study, we show that endothelial-transcytosed MPO 
mediates HOCl-dependent subendothelial matrix 
oxidation, involving covalent crosslinking of 
fibronectin, and that this triggers cell-matrix de-
adhesion driven by actomyosin-dependent tensile 
stress. We provide evidence that de-adhesion in 
response to HOCl-mediated matrix oxidation 
drives changes in key adhesion-dependent 
signaling processes and that diversion of MPO 
from HOCl production by SCN− or NO2− 
attenuates de-adhesion and associated signaling 
responses, despite the latter supporting MPO-
catalyzed matrix nitration. The ability of 
transcytosed MPO to disrupt endothelial integrity 
by targeted, HOCl-mediated subendothelial matrix 
oxidation may have important implications for the 
regulation of endothelial signaling and function 
during inflammation.  
 
 






Cell culture— Bovine aortic endothelial cells 
(ECs, Lonza; passages 4 - 9) were cultured in 
EBM-2 medium (Lonza) and routinely passaged 
on gelatin-coated tissue culture flasks.  
 
Cell Experiments— For experiments with ECs 
containing transcytosed MPO, ECs were initially 
cultured to confluence in EBM-2 medium (Lonza; 
with hydrocortisone omitted) on gelatin (Sigma; 
coated at 100 g/ml in PBS, 20 min, 22C). 
Confluent EC monolayers were then incubated for 
2 h with 20 nM purified human neutrophil MPO 
(Calbiochem) in HBSS supplemented with 0.2% 
BSA, culture conditions that permit maximal 
endothelial transcytosis of MPO (12,22). ECs 
containing transcytosed MPO were washed to 
remove unincorporated enzyme and then 
incubated in HBSS in the absence or presence of 
relevant reaction components including 1 mM 
methionine (Met), 100 μM 4-aminobenzoic acid 
hydrazide (ABAH), 100 μM SCN− and/or 100 μM 
NO2− for 15 min, or with cell signaling inhibitors 
(20 μM PP2, 40 μM blebbistatin, 10 μM Y-27632) 
for 30 min, prior to treatment with H2O2 (2 - 50 
μM) for up to 1 h. In some experiments, cells were 
treated with reagent HOCl added as a bolus. H2O2 
and HOCl solutions were prepared immediately 
before use and stock concentrations were 
determined spectrophotometrically (H2O2, ε240 
43.6 M-1 cm-1; HOCl, ε292 350 M-1 cm-1 at pH 12). 
For oxidant treatments, volumes were selected to 
ensure uniformity of oxidant exposure expressed 
relative to the adhesion area of cells (i.e. 1 ml for 
12-well plates, 80 l for 96-well plates).  
 For experiments with ECs adhered to 
fibronectin as the sole adhesive substrate, surfaces 
were first coated with bovine fibronectin (Sigma; 
5 g/ml / 22.7 nM in PBS, 2 h, 37C) and then 
blocked with BSA (0.2% in PBS, 0.5 h, 37C) 
prior to seeding of cells in serum-free media 
(medium-199 containing 1% BSA; 1 ml at 5  105 
cells/ml in 12-well plates, 200 l at 2.5  105 
cells/ml in 96-well plates). These cell seeding 
densities yielded a near-confluent layer of 
adherent cells within 2 h. In experiments to 
examine a role for fibronectin-bound MPO on EC 
adhesion, MPO was first bound to fibronectin-
coated surfaces (20 nM MPO in HBSS, 0.5 h, 
37C, with subsequent washing) prior to the 
seeding of cells. For surface binding of proteins, 
volumes were selected to ensure uniformity of 
protein coating, expressed relative to the adhesion 
area of cells (i.e. g protein/mm2; 1 ml for 12-well 
plates, 80 l for 96-well plates). ECs adhered to 
fibronectin or MPO-bearing fibronectin coated 
surfaces were then subjected to experimental 
treatments in the same manner as described above 
for ECs containing transcytosed MPO. 
For experiments to measure the propensity 
of ECs to adhere to fibronectin-bound surfaces 
previously exposed to MPO-derived oxidants, 
surfaces with MPO-bearing fibronectin were first 
treated with oxidants in the same manner as MPO-
containing ECs (see above). Oxidant-exposed 
surfaces were then incubated with Met (10 mM) 
for 10 min to quench residual reactive, surface-
bound protein chloramines followed by washing, 
seeding of ECs and measurement of cell adhesion 
by cell substrate impedance.  
 
Experiments with purified fibronectin— Purified 
bovine fibronectin (Sigma; 100 nmol/L, twice 
desalted on PD MiniTrap G-25 columns, GE 
Healthcare) was oxidized by pre-incubation with 
MPO (100 nM) for 15 min and exposure to H2O2 
(2 - 50 μM) for 1 h in the presence and absence of 
1 mM Met, 100 μM, ABAH, 100 μM SCN− or 100 
μM NO2−. 
 
Real time quantification of cell adhesion by cell-
substrate impedance— Cell-substrate impedance 
at the surface of 96-well gold microelectrode 
arrays (E-plate 96®, Roche), expressed as ‘cell 
index’, a dimensionless value proportional to the 
area of cell-substrate contact (24), was measured 
continuously following seeding of ECs and 
subsequent treatments by an xCelligence® system 
(Roche). During measurements, electrode arrays 
were housed in an incubator port maintained at 
37°C with 5% CO2 saturation. The relative number 
of attached ECs on electrode surfaces was 
quantified by crystal violet staining, as previously 
detailed (16). 
 
Live cell imaging— Differential interference 
contrast (DIC) images of live cells on gelatin- or 
fibronectin-coated 35mm glass-bottomed culture 
dishes (Fluorodish, World Precision Instruments) 




were recorded at 37C on a heated stage at 5 s 
intervals using a 63 water objective on a Leica 
TCS SP5 microscope. The projected area of 
randomly selected cells was quantified by 
manually tracing the membrane edge and 
quantifying the number of enclosed pixels using 
ImageJ (NIH). Change in area of individual cells 
over time was fitted to a single exponential decay 
using non-linear regression (least squares fitting; 
Prism 5, GraphPad Software) to determine the 
half-life of cell contraction. 
 
Measurement of H2O2— Cellular metabolism of 
exogenously added H2O2 was measured using an 
Amplex Red kit according to the manufacturer’s 
instructions (Molecular Probes).  
 
Western blotting— Following experiments, cell 
proteins and purified proteins were immediately 
harvested into reducing loading buffer. Proteins 
were separated on 3-8% Tris/Acetate NuPAGE® 
gels or 10% Bis/Tris NuPAGE® gels (Invitrogen), 
electroblotted to nitrocellulose (iBlot, Invitrogen) 
then probed with mouse monoclonal antibodies 
against fibronectin (1:2000; clone E3E, Millipore), 
HOCl-oxidized protein (1:25; cell supernatant, 
clone 2D10G9) (23), Src (1:1000; BD 
Biosciences), paxillin (1:1000: Cell Signaling), 
FAK (1:1000; Cell Signaling), and phospho-FAK 
Tyr-397 (1:1000; BD Biosciences) or with rabbit 
polyclonal antibodies against MPO (1:1000; 
Millipore), 3-nitrotyrosine (1:1000; Millipore), 
tubulin (1:1000; Sigma), phospho-paxillin Tyr-118 
(1:1000; Cell Signaling), phospho-Src Tyr-416 
(1:1000; Cell Signaling), phospho-Src Tyr-527 
(1:1000; Cell Signaling), MLC-2 (1:1000; Cell 
Signaling) and diphospho-MLC-2 Thr-18/Ser-19 
(1:1000; Cell Signaling). Proteins were visualized 
in gels by SyproRuby® staining (Invitrogen) and a 
Fuji FLA-5000 imaging system.  
 
Immunofluorescence— Cells on glass coverslips 
were processed for immunostaining by fixing with 
4% paraformaldehyde (22C, 20 min) and 
quenching free aldehydes with NH4Cl (50 mM) for 
5 min prior to washing in PBS. Cells were 
immunostained using mouse monoclonal 
antibodies against fibronectin (1:100), HOCl-
oxidized protein (2D10G9) (1:50) and paxillin 
(1:1000) or rabbit polyclonal antibodies against 
MPO (1:100) and fibronectin (1:100). Cy2-
conjugated goat anti-mouse (green) and Cy3-
conjugated donkey anti-rabbit (red) antibodies 
were employed as secondary antibodies. Cell 
nuclei were stained with DAPI (1:2000) and F-
actin was stained with Alexa 555-phalloidin 
(Invitrogen; 1:500). After washing with PBS, cells 
were mounted in Elvanol (Mowiol 4-88, Hoechst, 
Frankfurt, Germany). Laser confocal fluorescence 
images were recorded at room temperature using a 
63 oil objective on a Leica TCS SP5 microscope. 
Reconstructions of confocal images were rendered 
using Imaris software. 
 
Statistics— Statistical analyses were performed 
using one-way ANOVA with Newman Keul’s 
post-hoc testing with Prism 5 software. Statistical 





Endothelial-transcytosed MPO accumulates 
within the subendothelium where it oxidatively 
crosslinks matrix fibronectin in a HOCl-dependent 
manner— Incubation of confluent monolayers of 
ECs with MPO resulted in its uptake and 
accumulation within the subendothelial 
compartment, where it co-localized with matrix 
fibronectin (FIG. 1A), observations consistent with 
a previous study by Baldus et al. (12). ECs 
containing transcytosed MPO consumed 
exogenously added H2O2 at significantly enhanced 
rates compared to control cells (FIG. 1C). Laser 
confocal microscopy and immunofluorescence 
showed that H2O2 consumption by MPO-
containing ECs was accompanied by the formation 
of HOCl-oxidized protein within the 
subendothelial matrix, which co-localized with 
matrix fibronectin (FIG. 1B). Western blot 
analysis of protein extracts of these cells revealed 
extensive fibronectin crosslinking, reflected by 
loss of the parent fibronectin band and generation 
of non-reducible, high molecular weight (>250 
kDa) protein aggregates that were recognized by 
antibodies directed against fibronectin and HOCl-
oxidized protein (FIG. 2A). Production of HOCl-
oxidized proteins and fibronectin crosslinking 
were absent in control ECs treated with H2O2 
alone (FIG. 1B, FIG. 2A). Purified bovine 
fibronectin was similarly converted into HOCl-
modified, high molecular weight aggregates by 




exposure to MPO in the presence of H2O2 (FIG. 
2B). Inclusion of the MPO inhibitor ABAH or the 
HOCl-scavenger methionine (Met) prevented 
fibronectin cross-linking and generation of HOCl-
oxidized protein within cells (FIG. 2C) and with 
purified fibronectin (FIG. 2D), confirming MPO-
derived HOCl as the damaging species. Notably, 
HOCl derived from low micromolar 
concentrations of H2O2 (10 μM) by endothelial-
transcytosed MPO efficiently oxidized matrix 
fibronectin, as judged by the loss of the parent 
fibronectin band, whilst equivalent doses of 
reagent HOCl added as a bolus to the apical 
endothelial surface were ineffective (FIG. 2A). 
These data establish that transcytosed MPO 
mediates targeted matrix oxidation by producing 
HOCl focally within the subendothelial 
compartment. 
 
Thiocyanate and nitrite suppress HOCl-mediated 
fibronectin oxidation by endothelial-transcytosed 
MPO— SCN− and NO2− are important 
physiological MPO substrates that divert the 
enzyme from HOCl production to the generation 
of HOSCN and NO2, respectively with SCN− 
acting to stimulate (25) and NO2− acting to 
suppress (26) MPO catalytic turnover. In line with 
their expected effects on MPO turnover, SCN− 
(100 μM) accelerated, and NO2− (100 μM) 
attenuated H2O2 consumption by ECs containing 
transcytosed MPO (Supplementary FIG. 1). 
SCN− supplementation inhibited MPO-catalyzed 
formation of HOCl-oxidized protein and 
fibronectin modification/cross-linking in ECs 
(FIG. 3A) and with purified fibronectin (FIG. 3B). 
NO2− also blocked the formation of HOCl-
oxidized protein and attenuated fibronectin 
modification/crosslinking and promoted the 
generation of 3-nitrotyrosine, detected on high 
molecular weight protein aggregates, both in ECs 
(FIG. 3A) and on purified fibronectin (FIG. 3B). 
To identify the oxidant responsible for mediating 
fibronectin crosslinking in the presence of NO2− 
we added Met, which scavenges HOCl but not 
NO2 (27). Inclusion of Met suppressed fibronectin 
crosslinking and caused the majority of 3-
nitrotyrosine reactive protein to shift from high 
molecular weight aggregated material to a single 
band that co-migrated with the parent fibronectin 
band, both in ECs (FIG. 3C) and with purified 
fibronectin (FIG. 3D). Thus, while endothelial-
transcytosed MPO simultaneously promotes 
covalent crosslinking and nitration of matrix 
fibronectin in the presence of NO2−, covalent 
fibronectin crosslinking is mediated primarily by 
HOCl.  
 
MPO disrupts the cell-adhesive function of 
fibronectin in a HOCl-dependent manner— We 
next addressed the functional consequences of 
fibronectin oxidation by MPO, measured by its 
ability to support EC attachment and spreading. In 
these studies, MPO was first bound to fibronectin-
coated surfaces, unbound MPO removed by 
washing and the MPO-bearing fibronectin surfaces 
exposed to H2O2 for 30 min. EC attachment and 
spreading on native and MPO-oxidized fibronectin 
was then measured in real time using a cell-
substrate impedance electrode. 
 ECs seeded on native fibronectin in serum-free 
media were fully attached and spread within 2 h 
(FIG. 4A). Cell-substrate impedance values in 
fully-adhered cells, quantified as ‘cell index’ (a 
value proportional to the area of cell-matrix 
contact (24)), correlated linearly with cell number 
and increased with the density of fibronectin 
coating (20 g/mL) (Supplementary FIG. 2). 
Background EC adhesion levels on surfaces 
without fibronectin were negligible 
(Supplementary. FIG. 2), confirming that 
adhesion was solely dependent on this substrate.  
 Binding of MPO (20 nM) to approximately 
equimolar concentrations of fibronectin (coated at 
5 g/ml / 22 nM) prior to cell seeding did not alter 
the rate or extent of cell attachment and spreading, 
establishing that MPO does not mask fibronectin 
motifs that support EC adhesion (FIG. 4A). Pre-
treatment of the MPO-bearing fibronectin with 
low micromolar doses of H2O2 (≤10 μM) 
markedly impaired its ability to support 
subsequent EC attachment and spreading, with this 
loss of adhesive function abrogated by scavenging 
HOCl with Met and inhibiting MPO with ABAH 
(FIG. 4B). The MPO-dependent impairment of 
fibronectin’s cell adhesive function was also 
blocked by inclusion of SCN− or partially 
attenuated by NO2− (FIG. 4C). In reactions with 
NO2−, HOCl scavenging by Met completely 
preserved the cell adhesive function of fibronectin 
(FIG. 4C), despite the ability of MPO to catalyze 
tyrosine nitration of fibronectin under these 
conditions (FIGS. 3C, 3D). These findings 




establish that covalent modification/crosslinking 
of fibronectin by MPO-derived HOCl disrupts its 
cell adhesive function and that suppression of 
HOCl-mediated oxidative modification by SCN− 
and NO2− protects against this loss of function.   
 
Subendothelial MPO induces EC de-adhesion in a 
HOCl-dependent manner— Having established 
that MPO-derived HOCl disrupts the cell adhesive 
function of fibronectin (FIG. 4) and that 
fibronectin is an important target for HOCl 
produced by subendothelial MPO (FIGS. 1, 2), we 
next examined the capacity of endothelial-
transcytosed MPO to alter established EC cell-
matrix adhesion. To more specifically address the 
potential role of fibronectin oxidation by 
subendothelial-localized MPO in altering EC cell-
matrix adhesion, we performed equivalent studies 
with ECs adhered on fibronectin as the sole 
adhesive substrate. In these studies, MPO was first 
incorporated directly onto fibronectin-coated 
surfaces (as detailed in FIG. 4), ECs allowed to 
fully adhere for >2 h (cf. FIG. 4A) and changes in 
EC adhesion monitored after initiating MPO 
activity by exposure to H2O2. Changes in EC cell-
matrix adhesion elicited by oxidant production by 
transcytosed or fibronectin-bound MPO were 
quantified in real time using a cell-substrate 
impedance biosensor. 
 In ECs adhered on MPO-bearing fibronectin, 
H2O2 exposure provoked a rapid, time-dependent 
(FIG. 5A; p < 0.001 relative to control cells at 2 
min at 10 μM H2O2) and dose-dependent (FIG. 
5B) loss in cell-matrix contact. Quantification of 
ECs adhered to impedance electrodes by Crystal 
violet staining revealed that this decrease in cell-
matrix contact was independent of changes to the 
number of attached cells (Supplementary FIG. 
3A). ECs not only maintained cell attachment but 
remained viable during oxidant treatment, revealed 
by their ability to re-establish adhesion to control 
levels following the addition of fresh media 
(Supplementary FIG. 3B). A similarly rapid loss 
of cell-matrix contact in response to H2O2 
exposure was recapitulated in ECs containing 
transcytosed MPO (FIG. 6A). No loss of adhesion 
was detected in ECs exposed to equivalent doses 
of H2O2 in the absence of MPO (FIGS. 5A, 6A). 
Live cell imaging of MPO-containing EC exposed 
to H2O2 by differential interference contrast (DIC) 
microscopy (ECs adhered on MPO-bearing 
fibronectin – Supplementary Movie 1; ECs 
containing transcytosed MPO - Supplementary 
Movie 2, with representative frames at 0 and 2 
min after H2O2 exposure shown in FIG. 6C) 
revealed that the losses in cell-matrix contact were 
due to rapid membrane retraction and ‘rounding 
up’ of cells (i.e. ‘de-adhesion’) and confirmed that 
all cells remained attached to the substratum 
(Supplementary Movies 1 and 2).  
 Supplementation of ECs adhered on MPO-
bearing fibronectin with Met or ABAH (FIG. 5B) 
and SCN- or NO2- (FIG. 5C) prior to H2O2 
exposure attenuated MPO-mediated de-adhesion. 
The residual de-adhesion observed in the presence 
of SCN- and NO2- was completely prevented by 
scavenging spurious amounts of HOCl with Met 
(FIG. 5C). Inclusion of Met also completely 
abrogated de-adhesion in ECs containing 
transcytosed MPO and treated with H2O2 in the 
absence or presence of SCN- and NO2- (FIG. 6B).  
 Overall, these data establish that 
subendothelial-localized MPO triggers cell-matrix 
de-adhesion in a HOCl-dependent manner, and 
support that this involves disruption of the cell-
adhesive function of fibronectin. Moreover, they 
identify that SCN- and NO2- attenuate MPO-
induced de-adhesion in accordance with their 
capacity to suppress HOCl-mediated damage to 
fibronectin (FIG. 3). 
 
EC de-adhesion induced by subendothelial MPO 
is linked with HOCl-dependent changes in focal 
adhesion and cytoskeletal signaling— Cell-matrix 
adhesion involves the assembly of membrane 
domains called focal adhesions that co-ordinate 
cellular responses to local changes in the chemical 
and physical state of the extracellular matrix by 
transducing ‘outside-in’ signaling (28,29). 
Phosphorylation of the focal adhesion protein 
paxillin at Tyr-118 has emerged as a major 
mechanobiological signaling ‘switch’ that 
regulates responses to changes in cell-matrix 
adhesion, with loss of force transduction between 
the cell membrane and underlying matrix up-
regulating paxillin phosphorylation at this amino 
acid site (30). Also, phosphorylation of myosin 
light chain II (MLC-2) at Thr-18 and Ser-19, 
which positively regulates actomyosin 
contractility, plays a central role in the remodeling 
of the cytoskeleton and adhesive contacts in 
response to external stimuli (30,31). Therefore, we 




next investigated the extent to which matrix 
oxidation and disruption of cell-matrix adhesion 
by endothelial-localized MPO was linked with 
changes in the phosphorylation status of paxillin 
and MLC-2. 
 Exposure of MPO-containing ECs to H2O2 at 
≥10 μM triggered a time-dependent increase in the 
phosphorylation of paxillin at Tyr-118 that was 
apparent after 2 min oxidant addition and 
maintained up until 15 min before returning to 
baseline levels at 30 min (FIGS. 7A, B). Exposure 
of MPO-containing ECs to lower H2O2 doses (5 
μM), where EC adhesion was largely maintained 
(FIG. 6A), resulted in a time-dependent decrease 
in paxillin Tyr-118 phosphorylation (FIG. 7B). No 
alteration in paxillin phosphorylation was 
observed in control ECs exposed to equivalent 
doses of H2O2 in the absence of MPO (FIG. 7A). 
The dose-dependent modulation of paxillin 
phosphorylation by MPO (i.e., down-regulation at 
low oxidant dose or up-regulation at higher 
oxidant dose) was prevented by Met and 
suppressed in the presence of SCN- and NO2- plus 
Met (FIGS. 7C), identifying HOCl as the primary 
signaling oxidant produced by EC-localized MPO.  
 Tyr-118 of paxillin is a phosphorylation target 
for FAK or Src kinase (32). In MPO-containing 
ECs exposed to H2O2, while no marked change in 
Tyr-397 phosphorylated and hence activated FAK 
was apparent (FIG. 7A), exposure of these cells to 
25 μM H2O2 resulted in the time-dependent 
increase in phosphorylation of Src at its 
activation/auto-phosphorylation site Tyr-416 that 
paralleled the time-dependent increase in paxillin 
Tyr-118 phosphorylation (FIGS. 7A, C). 
Activation of Src by Tyr-416 phosphorylation can 
involve de-phosphorylation of an inhibitory 
phosphorylation site (Tyr-527) (33). Src Tyr-416 
phosphorylation and paxillin Tyr-118 
phosphorylation in MPO-containing ECs exposed 
to 25 μM H2O2 were not initially linked with Src 
Tyr-527 de-phosphorylation, however decreases in 
Tyr-527 phosphorylation were observed after 15 - 
30 min (FIG. 7C). Src Tyr-416 phosphorylation 
and Tyr-527 de-phosphorylation were both 
prevented by Met and suppressed in the presence 
of SCN− or NO2− plus Met (FIG. 7C). A role of 
Src kinase for HOCl-dependent paxillin 
phosphorylation was indicated by the ability of the 
Src kinase inhibitor PP2 to block both basal and 
MPO-induced paxillin Tyr-118 phosphorylation 
(FIG. 7D).  
 With respect to myosin II signaling, exposure 
of MPO-containing ECs to H2O2 resulted in the 
dose- (FIG. 7A) and time-dependent (FIG. 7B) 
increase in the cellular levels of di-phosphorylated 
MLC-2 (Tyr-18/Ser-19). MPO-induced MLC-2 
phosphorylation was inhibited by addition of Met 
or SCN- or NO2- plus Met (FIG. 7C), confirming 
its dependence on HOCl, and was prevented by 
inhibiting Rho kinase with Y-27632 (FIG. 7E). Y-
27632 did not suppress HOCl-mediated 
fibronectin oxidation, confirming that its activity 
reflected its action as a Rho kinase inhibitor (FIG. 
7E). 
 
EC de-adhesion induced by subendothelial MPO 
is dependent on actomyosin contractility— The 
preceding studies identify that HOCl produced by 
subendothelial-localized MPO elicits Rho kinase-
dependent MLC-2 phosphorylation, which signals 
for increased myosin II-dependent contractility, 
and alters Src-dependent paxillin phosphorylation. 
We next examined the potential functional role of 
these signaling events in MPO-induced de-
adhesion by employing pharmacological inhibitors 
of myosin II signaling and Src-dependent paxillin 
phosphorylation. Changes in EC adhesion were 
quantified over time by cell-substrate impedance 
and/or by measuring decreases in the projected 
area of individual cells by image analysis of time-
lapse DIC movies.  
 Src inhibition with PP2 had no impact on the 
rate of MPO-induced de-adhesion (FIG. 8B), 
indicating that while Src-dependent paxillin 
phosphorylation is a signaling response linked 
with de-adhesion it does not directly contribute to 
it. In contrast, inhibition of myosin II motor 
function with blebbistatin markedly abrogated 
membrane retraction from the substratum and 
from adjacent cells in MPO-containing ECs 
exposed to H2O2, both in ECs containing 
transcytosed MPO (FIG. 8A-D) and in ECs 
adhered on MPO-bearing fibronectin 
(Supplementary FIGS. 4A-D) (see also 
Supplementary Movies 1-4 for representative 
time-lapse DIC movies used for image analysis). 
Blebbistatin prevented EC de-adhesion without 
inhibiting HOCl-mediated fibronectin oxidation or 
MLC-2 phosphorylation (FIG. 7E), confirming 




that its inhibitory activity reflected its action as an 
inhibitor of myosin II motor function.  
 The rates of membrane retraction in individual 
cells during MPO-induced de-adhesion (measured 
as decreases in projected cell area over time) were 
quite uniform, with losses in cell area plateauing at 
ca. 50% of initial values and cells exhibiting 
average contraction half-lives of ca. 1 – 2 min both 
in ECs containing transcytosed MPO (FIGS. 8C, 
D) and in ECs adhered on MPO-bearing 
fibronectin (Supplementary FIGS. 4C, D). Of 
note, robust increases in Rho kinase-dependent 
MLC-2 phosphorylation occurred only after 5 min, 
when membrane retraction was already extensive 
(FIG. 7B). Furthermore, Rho kinase inhibition (Y-
27632) did not suppress the initial rapid phase of 
de-adhesion (<5 min following H2O2 exposure) 
and was protective only during the subsequent 
phase of de-adhesion (>5 min following H2O2 
exposure) (FIGS. 8A, B) when Rho kinase-
dependent MLC-2 phosphorylation was increased 
(cf. FIG. 7B). 
 Staining of MPO-containing ECs for F-actin 
and paxillin prior to (Supplementary FIG. 5A) 
and 10 min following H2O2 exposure 
(Supplementary FIG. 5B) showed that de-
adhesion involved extensive inward remodeling of 
the actin cytoskeleton and accumulation of F-actin 
and paxillin at the membrane periphery, with these 
effects abrogated by HOCl scavenging with Met 
(Supplementary FIG. 5C). Although Rho kinase-
dependent MLC-2 phosphorylation peaked within 
5 – 15 min following H2O2 exposure (FIG. 7B), 
this was not accompanied by an increase in long 
actin stress fibres and instead de-adhesion was 
characterized by a loss of pre-existing stress fibres 
(Supplementary FIGS. 5A, B).  
Overall, these findings support that while up-
regulation of Rho kinase-dependent contractility 
contributes to the overall extent of MPO-induced 
de-adhesion, the initial, rapid phase of membrane 
retraction represents a response to oxidative 
disruption of cell-matrix contacts by MPO-derived 
HOCl, and is primarily driven by pre-existing 





During vascular inflammation, MPO is released 
from activated leukocytes and accumulates within 
the subendothelial extracellular matrix by binding 
to and transcytosing the endothelium (12,19). 
Compelling clinical and experimental evidence 
has identified endothelial-transcytosed MPO as a 
key mediator of impaired NO signaling in 
inflammatory vascular responses and in human 
cardiovascular disease, with this thought to reflect 
its ability to efficiently intercept and oxidatively 
consume endothelial-derived NO within the 
subendothelial space (7,10,11). However, 
subendothelial-localized MPO is also anatomically 
positioned to impact on endothelial morphology 
and signaling by oxidatively modifying the 
structure and function of adhesive extracellular 
matrix proteins (12,15,16). 
 This study shows for the first time that 
subendothelial-localized MPO utilizes low 
micromolar concentrations of H2O2 to mediate 
targeted, HOCl-dependent oxidation of the 
subendothelial matrix, with this involving covalent 
modification/crosslinking of matrix fibronectin. 
Employing real time cell-substrate impedance 
biosensor measurements and quantitative live cell 
image analysis, we showed that HOCl-mediated 
oxidation of the subendothelial matrix triggers 
rapid retraction of the cell membrane from the 
substratum and from adjacent ECs (de-adhesion). 
EC de-adhesion was linked with the activation of 
Src and modulation of Tyr-118 phosphorylation of 
paxillin, a key focal adhesion-dependent signaling 
process, as well as Rho kinase-dependent MLC-2 
phosphorylation. Of these signaling events, MPO-
induced EC de-adhesion were dependent on the 
actomyosin contractile machinery as inhibition of 
myosin II and Rho kinase-mediated MLC-2 
phosphorylation significantly reduced the overall 
rate of membrane retraction. 
 Previous studies have shown that transcytosed 
MPO associates basolaterally with fibronectin and 
locally catabolizes NO2- to the nitrating radical 
NO2, conferring specificity of MPO-mediated 
protein tyrosine nitration to fibronectin (12). 
Immunohistochemical studies support that 
fibronectin is an important target for MPO-derived 
NO2 in inflammatory vascular disorders, with 
MPO, fibronectin and tyrosine nitrated proteins 
having been shown to co-localize in diseased 
human vessels (19). However, the functional 
implications of NO2 production within the 
endothelium by MPO have not been previously 
investigated. The current study reveals that in the 




presence of NO2- subendothelial MPO 
concomitantly catalyzes HOCl-dependent 
crosslinking and tyrosine nitration of matrix 
fibronectin. However, HOCl-mediated reactions 
were shown to be primarily responsible for 
triggering EC de-adhesion and associated cell 
signaling events: Scavenging of HOCl with Met 
markedly attenuated fibronectin crosslinking and 
cell signaling responses, but did not prevent 
fibronectin nitration.  
 Another biologically important MPO substrate 
is SCN−, which is derived primarily from dietary 
sources (e.g., broccoli) and is elevated in smokers. 
Currently, there is considerable interest in whether 
diversion of MPO from HOCl production by SCN− 
to instead produce the thiol-reactive oxidant 
HOSCN is protective or deleterious in the context 
of inflammatory vascular conditions (34,35). Our 
finding that SCN- accelerates H2O2 metabolism yet 
suppresses HOCl production by EC-localized 
MPO is indicative of local production of HOSCN. 
Despite this, SCN− supplements were protective 
against MPO-induced EC de-adhesion and 
associated signaling responses, indicating the 
HOSCN produced by subendothelial MPO is 
functionally silent in this regard. These findings 
are consistent with other findings that identify a 
protective, antioxidant function for SCN− against 
MPO-mediated EC injury (34). 
 Model studies employing purified fibronectin 
as the sole adhesive substrate provided strong 
evidence that induction of EC de-adhesion by 
MPO-derived HOCl involves disruption of the 
cell-adhesive function of fibronectin. Thus, 
oxidation of fibronectin by MPO-derived HOCl 
readily impaired its ability to support EC 
attachment and spreading and this loss in function 
correlated well with the capacity of HOCl, 
produced at the basolateral surface of ECs by 
fibronectin-bound MPO, to disrupt established EC 
adhesion on fibronectin. In accordance with their 
ability to suppress HOCl-mediated fibronectin 
modification/crosslinking, SCN− and NO2− 
prevented MPO-induced impairment of attachment 
and spreading of ECs on, and de-adhesion of ECs 
from fibronectin. 
 Whilst our data identify a causal role for 
HOCl-mediated matrix oxidation in triggering EC 
de-adhesion, we showed that actomyosin tensile 
forces significantly accelerate this process. Thus, 
the rate of de-adhesion triggered by H2O2 exposure 
in MPO-containing ECs was markedly attenuated 
by the inhibition of myosin II motor function with 
blebbistatin. Up-regulation of Rho kinase-
dependent contractility contributed to the MPO-
induced EC de-adhesion, but not during the initial 
rapid phase of membrane retraction, which 
preceded robust increases in Rho kinase-
dependent MLC-2 phosphorylation and was not 
attenuated by Rho kinase inhibition.  
 Our data support a model where 
subendothelial-localized MPO catalyzes targeted, 
HOCl-mediated matrix oxidation that disrupts 
adhesive forces at the cell-matrix interface to 
trigger membrane retraction driven by pre-existing 
tensile force within the actin cytoskeleton 
(SCHEME 1A, B). Notably, other recent studies 
identify that targeted disruption of cell-matrix 
contacts by electrochemical means likewise 
provokes rapid cell contraction driven by pre-
existing actomyosin tensile stress (36). 
 As well as mechanically coupling the actin 
cytoskeleton to the subendothelial matrix, 
adhesive contacts are enriched in cytoplasmic 
signaling proteins and rapidly transduce 
mechanical signals provided by changes in cell-
matrix adhesion into intracellular phosphorylation 
events. This ‘outside-in’ signaling, in which 
paxillin phosphorylation plays a central regulatory 
role, allows cells to respond rapidly and 
sensitively to chemical and physical changes in the 
extracellular matrix and engages signaling 
networks that control cell shape, motility, 
proliferation and survival (28-31).  
 We propose that the focal disruption of cell-
matrix contacts by HOCl in the subendothelium 
drives signaling changes by altering cell-matrix 
mechanotransduction (SCHEME 1C). Paxillin Tyr-
118 phosphorylation is negatively regulated by 
force transduction at focal adhesions (i.e. cell-
matrix traction) (30) and the increase in 
phosphorylation observed at this site at higher 
oxidant doses is fully consistent with a global loss 
in cell-matrix traction triggered by HOCl-
mediated matrix oxidation. Phosphorylation of 
paxillin at Tyr-118 generates docking sites for 
SH2 domain containing proteins (29) and engages 
signaling networks that regulate the assembly of 
new adhesive contacts (30). Notably, the levels of 
paxillin phosphorylation were initially maintained 
and chronically down-regulated during de-
adhesion at lower oxidant doses, where matrix 




oxidation and de-adhesion was less extensive, with 
this consistent with compensatory increases in 
cell-matrix traction at pre-existing and/or newly 
formed adhesive contacts (30).  
 Another important novel aspect of this work is 
the finding that HOCl produced subendothelially 
by MPO induces Rho kinase-dependent MLC-2 
di-phosphorylation at Tyr-18 and Ser-19, and Src 
activation as indexed by Tyr-416 phosphorylation 
and Tyr-527 de-phosphorylation. Together with 
alterations in paxillin phosphorylation, MLC-2 
phosphorylation and Src activation represent key 
signaling processes involved in adhesion 
responses (30,31). The specificity of these 
responses to the action of MPO-derived HOCl 
indicates that they may be functionally linked to 
changes in cell-matrix mechanotransduction (see 
discussion below). Notably, previous studies 
identify that loss of cell adhesion alone can trigger 
increases in Src activation and paxillin 
phosphorylation (37,38).  
 Significantly, no previous study has addressed 
the possibility that oxidants might drive changes in 
cell signaling by altering cell-matrix 
mechanotransduction. Our proposed model of 
‘outside-in’ redox signaling (SCHEME 1) differs 
from the conventional model of redox signaling in 
that it involves oxidants modifying extracellular 
proteins and generating mechanical signals to 
propagate intracellular phosphorylation events 
instead of directly modifying and altering the 
activity of intracellular signaling proteins.  
 We do not exclude that ‘conventional’ redox 
signaling mechanisms contribute to the signaling 
responses elicited by subendothelial-localized 
MPO. HOCl could contribute to the observed 
signaling responses (paxillin Tyr-118 
phosphorylation, Src Tyr-118 phosphorylation/ 
Tyr-527 de-phosphorylation or MLC-2 Tyr-18/ 
Ser-19 phosphorylation), by directly oxidizing 
critical cysteine residues present on RhoA (which 
activates Rho kinase) and Src, leading to their 
activation (33,39,40) or by oxidizing active site 
cysteines in regulatory protein phosphatases. 
However, given that HOSCN is predominantly a 
thiol-selective oxidant (18), the ability of SCN- to 
suppress these signaling responses is not 
consistent with a role for conventional redox 
signaling as if the case the formation of HOSCN 
by EC-localized MPO would also be expected to 
promote the relevant signaling events. 
Furthermore, kinetic considerations on the 
reactivity of oxidants predicts that HOCl exerts its 
biological effects by oxidizing targets within a 
very short distance of its site of production (41). In 
line with this prediction, our current data identifies 
that HOCl produced by endothelial-transcytosed 
MPO mediates focal oxidation of matrix proteins 
within the subendothelial compartment to alter 
adhesion and adhesion-dependent signaling. We 
propose that this involves HOCl-mediated 
impairment of the function of the cell-adhesion 
(integrin- and/or heparin-binding) motifs of 
fibronectin. Indeed, the lack of cysteine and 
tyrosine residues in these adhesion motifs, and 
hence their resistance to functional damage by 
HOSCN and NO2, could explain why diversion of 
MPO from HOCl production by SCN- and NO2- 
was protective against de-adhesion and associated 
signaling responses.  
 Physiological redox signaling processes are 
increasingly recognized to be highly regulated, 
involving targeted, oxidative modification of 
specific proteins, with signaling specificity 
achieved through spatial association of oxidant-
generating enzymes and target proteins within 
specific cellular compartments (1,42). 
Interestingly, the alteration of endothelial 
signaling by subendothelial matrix-bound MPO 
fits within this paradigm. It is therefore tempting 
to speculate that the delivery of MPO to the 
subendothelial compartment by endothelial-
transcytosis to promote HOCl-mediated matrix 
oxidation might serve an unforseen regulatory 
function during inflammatory vascular responses. 
However, its potential pathophysiological 
significance is clear: Our present findings identify 
that matrix oxidation resulting from the production 
of low, physiological fluxes of HOCl by 
subendothelial-localized MPO triggers a rapid loss 
in endothelial cell-matrix adhesion and increase in 
membrane retraction, events that will significantly 
perturb the integrity of the endothelium. These 
processes could play a key pathological role in 
inflammatory vascular conditions by promoting 
tissue oedema and compromising the anti-
inflammatory/anti-thrombogenic function of the 
endothelium by exposing intimal proteins.  
  







1. Thomas, S. R., Witting, P. K., and Drummond, G. R. (2008) Antioxid Redox Signal 10, 1713-
1765 
2. Lum, H., and Roebuck, K. A. (2001) Am J Physiol Cell Physiol 280, C719-741 
3. Komarova, Y., and Malik, A. B. (2010) Annu Rev Physiol 72, 463-493 
4. Orr, A. W., Stockton, R., Simmers, M. B., Sanders, J. M., Sarembock, I. J., Blackman, B. R., and 
Schwartz, M. A. (2007) J Cell Biol 176, 719-727 
5. Sun, C., Wu, M. H., and Yuan, S. Y. (2011) Circulation 124, 48-57 
6. Vita, J. A., Brennan, M. L., Gokce, N., Mann, S. A., Goormastic, M., Shishehbor, M. H., Penn, 
M. S., Keaney, J. F., Jr., and Hazen, S. L. (2004) Circulation 110, 1134-1139 
7. Baldus, S., Heitzer, T., Eiserich, J. P., Lau, D., Mollnau, H., Ortak, M., Petri, S., Goldmann, B., 
Duchstein, H. J., Berger, J., Helmchen, U., Freeman, B. A., Meinertz, T., and Munzel, T. (2004) 
Free Radic Biol Med 37, 902-911 
8. Baldus, S., Heeschen, C., Meinertz, T., Zeiher, A. M., Eiserich, J. P., Munzel, T., Simoons, M. L., 
and Hamm, C. W. (2003) Circulation 108, 1440-1445 
9. Brennan, M. L., Penn, M. S., Van Lente, F., Nambi, V., Shishehbor, M. H., Aviles, R. J., 
Goormastic, M., Pepoy, M. L., McErlean, E. S., Topol, E. J., Nissen, S. E., and Hazen, S. L. 
(2003) N Engl J Med 349, 1595-1604 
10. Eiserich, J. P., Baldus, S., Brennan, M. L., Ma, W., Zhang, C., Tousson, A., Castro, L., Lusis, A. 
J., Nauseef, W. M., White, C. R., and Freeman, B. A. (2002) Science 296, 2391-2394 
11. Rudolph, T. K., Wipper, S., Reiter, B., Rudolph, V., Coym, A., Detter, C., Lau, D., Klinke, A., 
Friedrichs, K., Rau, T., Pekarova, M., Russ, D., Knoll, K., Kolk, M., Schroeder, B., Wegscheider, 
K., Andresen, H., Schwedhelm, E., Boeger, R., Ehmke, H., and Baldus, S. (2011) Eur Heart J 
(doi: 10.1093/eurheartj/ehr193). 
12. Baldus, S., Eiserich, J. P., Mani, A., Castro, L., Figueroa, M., Chumley, P., Ma, W., Tousson, A., 
White, C. R., Bullard, D. C., Brennan, M. L., Lusis, A. J., Moore, K. P., and Freeman, B. A. 
(2001) J Clin Invest 108, 1759-1770 
13. Baldus, S., Rudolph, V., Roiss, M., Ito, W. D., Rudolph, T. K., Eiserich, J. P., Sydow, K., Lau, 
D., Szocs, K., Klinke, A., Kubala, L., Berglund, L., Schrepfer, S., Deuse, T., Haddad, M., Risius, 
T., Klemm, H., Reichenspurner, H. C., Meinertz, T., and Heitzer, T. (2006) Circulation 113, 
1871-1878 
14. Vissers, M. C., and Thomas, C. (1997) Free Radic Biol Med 23, 401-411 
15. Rees, M. D., Kennett, E. C., Whitelock, J. M., and Davies, M. J. (2008) Free Radic Biol Med 44, 
1973-2001 
16. Rees, M. D., Whitelock, J. M., Malle, E., Chuang, C. Y., Iozzo, R. V., Nilasaroya, A., and 
Davies, M. J. (2010) Matrix Biol 29, 63-73 
17. Hampton, M. B., Kettle, A. J., and Winterbourn, C. C. (1998) Blood 92, 3007-3017 
18. Davies, M. J., Hawkins, C. L., Pattison, D. I., and Rees, M. D. (2008) Antioxid Redox Signal 10, 
1199-1234 
19. Baldus, S., Eiserich, J. P., Brennan, M. L., Jackson, R. M., Alexander, C. B., and Freeman, B. A. 
(2002) Free Radic Biol Med 33, 1010 
20. Hazell, L. J., Arnold, L., Flowers, D., Waeg, G., Malle, E., and Stocker, R. (1996) J Clin Invest 
97, 1535-1544 
21. Malle, E., Waeg, G., Schreiber, R., Grone, E. F., Sattler, W., and Grone, H. J. (2000) Eur J 
Biochem 267, 4495-4503 
22. Tiruppathi, C., Naqvi, T., Wu, Y., Vogel, S. M., Minshall, R. D., and Malik, A. B. (2004) Proc 
Natl Acad Sci U S A 101, 7699-7704 
23. Malle, E., Hazell, L., Stocker, R., Sattler, W., Esterbauer, H., and Waeg, G. (1995) Arterioscler 
Thromb Vasc Biol 15, 982-989 




24. Solly, K., Wang, X., Xu, X., Strulovici, B., and Zheng, W. (2004) Assay Drug Dev Technol 2, 
363-372 
25. van Dalen, C. J., Whitehouse, M. W., Winterbourn, C. C., and Kettle, A. J. (1997) Biochem J 327 
( Pt 2), 487-492 
26. van Dalen, C. J., Winterbourn, C. C., Senthilmohan, R., and Kettle, A. J. (2000) J Biol Chem 275, 
11638-11644 
27. Prutz, W. A., Monig, H., Butler, J., and Land, E. J. (1985) Arch Biochem Biophys 243, 125-134 
28. Geiger, B., Spatz, J. P., and Bershadsky, A. D. (2009) Nat Rev Mol Cell Biol 10, 21-33 
29. Brown, M. C., and Turner, C. E. (2004) Physiol Rev 84, 1315-1339 
30. Zaidel-Bar, R., Milo, R., Kam, Z., and Geiger, B. (2007) J Cell Sci 120, 137-148 
31. Vicente-Manzanares, M., Ma, X., Adelstein, R. S., and Horwitz, A. R. (2009) Nat Rev Mol Cell 
Biol 10, 778-790 
32. Bellis, S. L., Miller, J. T., and Turner, C. E. (1995) J Biol Chem 270, 17437-17441 
33. Giannoni, E., Taddei, M. L., and Chiarugi, P. (2010) Free Radic Biol Med 49, 516-527 
34. Xu, Y., Szep, S., and Lu, Z. (2009) Proc Natl Acad Sci U S A 106, 20515-20519 
35. Wang, Z., Nicholls, S. J., Rodriguez, E. R., Kummu, O., Horkko, S., Barnard, J., Reynolds, W. F., 
Topol, E. J., DiDonato, J. A., and Hazen, S. L. (2007) Nat Med 13, 1176-1184 
36. Wildt, B., Wirtz, D., and Searson, P. C. (2009) Nat Methods 6, 211-213 
37. Loza-Coll, M. A., Perera, S., Shi, W., and Filmus, J. (2005) Oncogene 24, 1727-1737 
38. Giannoni, E., Buricchi, F., Grimaldi, G., Parri, M., Cialdai, F., Taddei, M. L., Raugei, G., 
Ramponi, G., and Chiarugi, P. (2008) Cell Death Differ 15, 867-878 
39. Aghajanian, A., Wittchen, E. S., Campbell, S. L., and Burridge, K. (2009) PLoS One 4, e8045 
40. Knock, G. A., and Ward, J. P. (2011) Antioxid Redox Signal 15, 1531-1547 
41. Winterbourn, C. C. (2008) Nat Chem Biol 4, 278-286 




*This work was supported by a National Health and Medical Research Council (NHMRC) Project Grant 
568721 (SRT) and, in part, by a UNSW Faculty of Medicine Faculty Research Grant (MDR). SRT 
received support from an NHMRC RD Wright Career Development Award (401113). 
 
1Address correspondence to:  
Dr. Shane R. Thomas, Centre for Vascular Research and School of Medical Sciences, Level 3 Lowy 
Cancer Research Centre, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, 
Australia. Tel: +61-2-9385 2582; Fax: +61-2-9385 1389; Email: shane.thomas@unsw.edu.au 
 
The abbreviations used are: ABAH, 4-aminobenzoic acid hydrazide; PP2, 4-amino-5-(4-chlorophenyl)-7-
(dimethylethyl)pyrazolo[3,4-d]pyrimidine; ECs, bovine aortic endothelial cells; FAK, focal adhesion 
kinase; HBSS, Hank’s balanced salt solution; HOCl, hypochlorous acid; HOSCN, hypothiocyanous acid; 
MPO, myeloperoxidase; MLC-2, myosin light chain 2; NO2-, nitrite; NO2 nitrogen dioxide radical; PBS, 










FIGURE 1. Endothelial-transcytosed MPO localizes with matrix fibronectin and mediates HOCl-
dependent protein oxidation. EC monolayers were incubated with MPO (20 nM) for 2 h and 
unincorporated MPO removed by washing. MPO-containing ECs were then incubated with H2O2 (50 μM) 
for a further 1 h. (A) MPO-containing ECs prior to H2O2 treatment were fixed and imaged by laser 
confocal fluorescence microscopy using antibodies against fibronectin (FN; green) or MPO (red). (B) 
MPO-containing ECs treated with H2O2 were fixed and imaged by laser confocal fluorescence 
microscopy using antibodies against fibronectin (FN; green) or HOCl-oxidized protein (clone 2D10G9; 
red).  Nuclei were counterstained with DAPI (blue). Bar = 50 m.  (C) H2O2 consumption by control and 
MPO-containing ECs over 1 h was measured by assaying cell supernatants by the Amplex Red assay at 
the indicated times. Data represent the mean  SEM, n = 3 independent experiments, ** = p < 0.01 
relative to control cells.  
 
FIGURE 2. Endothelial-transcytosed MPO oxidatively crosslinks matrix fibronectin in a HOCl-
dependent manner. (A, B) EC monolayers were incubated with MPO (20 nM) for 2 h and 
unincorporated MPO removed by washing. Control and MPO-containing ECs were non-treated or treated 
with H2O2 (1-50 μM) for 1 h in the absence and presence of Met (1 mM) or ABAH (100 μM). In (A), 
control ECs were also treated with a bolus of reagent HOCl (10 μM) for 1 h. (C, D) Purified bovine 
fibronectin (100 nM) was pre-incubated with MPO (100 nM) for 15 min) prior to addition of H2O2 (0 - 50 
μM) and incubation for a further 1 h in the absence and presence of Met (1 mM) or ABAH (100 μM). 
Cell proteins and purified proteins were analyzed by Western blotting (3-8% gels) under reducing 
conditions using antibodies against fibronectin (FN) or HOCl-oxidized protein (clone 2D10G9). In (A), 
tubulin (55 kDa) was used as a protein loading control. In (C), protein bands of the purified proteins were 
visualized in the gels by Syproruby® staining (i.e., native FN monomer detected at 250 kDa and MPO -
chain monomer detected at ~60 kDa). Western blot/gel images are reduced by 50% on the vertical scale.  
 
FIGURE 3. Thiocyanate and nitrite suppress HOCl-mediated fibronectin oxidation by endothelial-
transcytosed MPO. (A, B) EC monolayers were incubated with MPO (20 nM) for 2 h and 
unincorporated MPO removed by washing. Control and MPO-containing ECs were then non-treated or 
treated with H2O2 (50 μM) for 1 h in the absence and presence of SCN− (100 μM), NO2− (100 μM) or Met 
(1 mM). (C, D) Purified bovine fibronectin (FN; 100 nM) was incubated with MPO (100 nM, 15 min), 
then non-treated or treated with H2O2 (50 μM) for 1 h in the absence and presence of SCN− (100 μM), 
NO2- (100 μM) or Met (1 mM). (A, B) Cell proteins or (C, D) purified proteins were analyzed by Western 
blotting (3-8% gels) using antibodies against FN, HOCl-oxidized protein (clone 2D10G9) or 3-
nitrotyrosine (NO2Tyr). Western blot/gel images are reduced by 50% in the vertical scale. 
 
FIGURE 4. MPO-derived HOCl impairs the cell-adhesive function of fibronectin. Bovine fibronectin 
was coated at 5 g/ml (ca. 22 nM) and incubated with MPO (20 nM) for 30 min before unbound MPO 
was removed by washing. Fibronectin and MPO-bearing fibronectin surfaces were then non-treated or 
treated with H2O2 (1-10 μM) for 1 h in the absence and presence of Met (1 mM), ABAH (100 μM), SCN− 
(100 μM) or NO2− (100 μM). Met (10 mM, 10 min) was then added to quench chloroamines, surfaces 
washed and ECs seeded. EC adhesion and spreading was then measured 2 h after cell seeding by cell-
substrate impedance. (A) EC adhesion onto fibronectin (control) or MPO-bearing fibronectin (MPO) 
(without H2O2 pre-treatment) over the 2 h period after cell seeding. (B) EC adhesion (2 h post-seeding) on 
non-treated or H2O2-treated fibronectin or MPO-bearing fibronectin in the absence and presence of Met or 
ABAH. (C) EC adhesion (2 h post-seeding) on MPO-bearing fibronectin treated with H2O2 in the absence 
and presence of SCN−, NO2− and/or Met. Data represent the mean  SEM, n = 3. *** = p < 0.001 relative 
to EC adhesion onto MPO-bearing fibronectin without H2O2 treatment. # = p < 0.05. 




FIGURE 5. Subendothelial MPO induces EC de-adhesion from fibronectin in a HOCl-dependent 
manner. Bovine fibronectin was coated at 5 g/ml (ca. 22 nM) and incubated with MPO (20 nM) for 30 
min before unbound MPO was removed by washing. ECs were seeded and allowed to fully adhere over 2 
h onto fibronectin and MPO-bearing fibronectin surfaces (cf. Fig. 4A) before non-treatment or treatment 
with H2O2 (1-10 μM) in the absence and presence of Met (1 mM), ABAH (100 μM), SCN− (100 μM) or 
NO2− (100 μM). Oxidant-induced changes in cell adhesion were measured by cell-substrate impedance 
over the ensuing 30 min after H2O2 addition; cell index data is normalized to the cell index value at the 
time of H2O2 addition which was given a value of 1. (A) Time-dependent changes in cell adhesion of ECs 
pre-adhered onto fibronectin (control) or MPO-bearing fibronectin (MPO) and then non-treated or treated 
with H2O2 (10 μM). (B) Cell adhesion of ECs pre-adhered onto fibronectin or MPO-bearing fibronectin 
following 30 min treatment with H2O2 (1-10 μM) in the absence or presence of Met or ABAH. (C) Cell 
adhesion of ECs pre-adhered onto MPO-FN following 30 min after treatment with H2O2 in the absence or 
presence of SCN−, NO2− and NO2−/Met. Data represent the mean  SEM, n = 6 (A) or n = 3 (B, C). * = p 
< 0.05, ** = p < 0.01 and *** = p < 0.001 relative to cell adhesion changes of MPO-containing ECs 
without H2O2 treatment. # = p < 0.05. 
 
FIGURE 6. Endothelial-transcytosed MPO induces EC de-adhesion in a HOCl-dependent manner. 
EC monolayers were incubated with MPO (20 nM) for 2 h and unincorporated MPO removed by 
washing. Control and MPO-containing ECs were then non-treated or treated with H2O2 (5 or 25 μM) in 
the absence and presence of Met (1 mM), SCN− (100 μM) or NO2− (100 μM). Oxidant-induced changes to 
cell adhesion were then measured by cell-substrate impedance; cell index data is normalized to the cell 
index value at the time of H2O2 addition which was given a value of 1. (A) Time-dependent changes in 
cell adhesion of control or MPO-containing ECs following treatment with the indicated concentrations of 
H2O2. (B) Cell adhesion changes of MPO-containing ECs after 30 min treatment with H2O2 in the absence 
or presence of Met, SCN−, NO2− or Met/NO2−. Data represent the mean  SEM, n = 6. *** = p < 0.001 
relative to MPO-containing ECs without H2O2 exposure. # = p < 0.05. (C) Frames from a representative 
live cell DIC microscopy movie (Supplementary Movie 2) of MPO-containing ECs before (0 min) and 
after treatment with H2O2 (10 μM) for 2 min. Bar = 50 m. 
 
FIGURE 7. Endothelial-transcytosed MPO alters the phosphorylation of paxillin, Src and MLC-2 in 
a HOCl-dependent manner. (A-E) EC monolayers were incubated with MPO (20 nM) for 2 h and 
unincorporated MPO removed by washing. Control and MPO-containing ECs were then treated with 
H2O2 (2 - 25 μM) in the absence or presence of other reaction components (1 mM Met, 100 μM ABAH, 
100 μM SCN- or 100 μM NO2-) or selective inhibitors of myosin II (blebbistatin, 40 μM), Rho kinase (Y-
27632, 10 μM) or Src kinase (PP2, 20 μM). At the indicated times after the addition of H2O2, cellular 
protein extracts were prepared and analyzed by Western blotting for the levels of fibronectin (FN), 
paxillin Tyr-118 phosphorylation, paxillin, Src Tyr-416 or Tyr-527 phosphorylation, Src, FAK Tyr-397 
phosphorylation, FAK, MLC-2 Tyr-18/Ser-19 di-phosphorylation and MLC-2.  
 
FIGURE 8. EC de-adhesion induced by endothelial-transcytosed MPO involves myosin II-mediated 
contractility. EC monolayers were incubated with MPO (20 nM) for 2 h and unincorporated MPO 
removed by washing. MPO-containing ECs were then treated with H2O2 (10 μM) for 15 min in the 
absence or presence of inhibitors of myosin II (blebbistatin, 40 μM), Rho kinase (Y-27632, 10 μM) or Src 
kinase (PP2, 20 μM). (A, B) Changes in cell adhesion, measured by cell-substrate impedance, in MPO-
containing ECs after treatment with H2O2 in the absence or presence of blebbistatin, Y-27632 or PP2. (B) 
EC adhesion 15 min after H2O2 addition. Data represent the mean  SEM, n = 6. Cell index data is 
normalized to the cell index value at the time of H2O2 addition which was given a value of 1. (C, D) 
Changes in cell area, measured by image analysis of time-lapse DIC microscopy movies, in MPO-
containing ECs after treatment with H2O2 in the absence or presence of blebbistatin (n = 10 cells, 2 
replicate movies, 5 randomly selected cells per movie - cf. Supplementary Movies 2 and 4); cell area 




data are normalized to the cell area value at the time of H2O2 addition which was given a value of 1. (C, 
inset) cell contraction half-lives determined by fitting the data to a single exponential decay to cell area 
values in individual cells over time. (D) Cell area, expressed as m2, before (0 min) and 13 min after 
H2O2 addition.  *** = p < 0.001 relative to MPO-containing ECs (B) without or (D) prior to H2O2 
exposure. # = p < 0.05. 
 
 
SCHEME 1. Proposed model of MPO-induced EC de-adhesion and ‘outside-in’ redox signaling. (A) 
MPO binds to the subendothelial matrix and mediates targeted HOCl-dependent matrix oxidation that (B) 
disrupts cell-matrix contact, leading to (C) membrane retraction driven by unopposed tension in the actin 
cytoskeleton and alteration of adhesion-dependent signaling. ‘pax’ = paxillin.  
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